NRAS G12V

Clinical trials for NRAS G12V explained in plain language.

Never miss a new study

Get alerted when new NRAS G12V trials appear

Sign up with your email to follow new studies for NRAS G12V, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 2

New targeted drug hopes to shrink NRAS-Driven cancers

Disease control Recruiting now

This early-phase study tests a new oral drug, RLY-8161, designed to block a specific cancer-driving protein called NRAS. It is for people with advanced melanoma or other solid tumors that have an NRAS mutation and have not responded to standard treatments. The main goals are to f…

Matched conditions: NRAS G12V

Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control

Last updated Jul 04, 2026 00:00 UTC

NRAS G12V

Get alerted when new NRAS G12V trials appear

New targeted drug hopes to shrink NRAS-Driven cancers